Table 6.

Patients with INSTI resistance exposed to dolutegravir as the only INSTI.

						Antiretroviral therapy†			Drug resistance mutations‡
Gender	Age	Transmision route*	Geographical origin	Years from diagnosis	Genetic form	Current	Previous	Adherence	PI	NRTI	NNRTI	INSTI	Resistance level to DTG
F	18	Vertical	Sub-Saharan Africa	18	CRF02_AG	DTG + ABC + 3TC	EFV + ABC + 3TC	Poor	No	L74V	K103N, V179E	R263K	Intermediate
M	31	ND	ND	<1	CRF02_AG	TDF + EFV + 3TC	DTG + ABC + 3TC	Poor	No	K70E, L74V, M184V	K103N, G190A	E157Q, R263K	Intermediate
M	20	MSM	Latin America	<1	B	DTG + ABC + 3TCƪ	3TC + TDF + DRV/r	Good	No	M184V	No	R263K	Intermediate
M	56	PWID	Spain	31	B	DTG + ABC + 3TC	Multiple	Poor	No	No	No	S230R	Low-Level
F	53	ND	ND	31	B	DTG + 3TC	ABC + 3TC + ETR	Poor	No	No	E138A	S230R	Low-Level
F	65	ND	ND	7	D	TDF + FTC + DTG	None	Poor	No	No	No	G163R	Susceptible
M	52	HET	Sub-Saharan Africa	12	CRF02_AG	DTG + ABC + 3TC	ABC + 3TC + EFV	Poor	NA	NA	NA	G163K	Susceptible
M	26	HSH	Latin America	<1	B	TDF + FTC + DTG	None	Good	No	No	No	G163R	Susceptible

^*PWID, person who injects drugs; MSM, man who has sex with men; HET, heterosexual. ND, no data.^†DTG, Dolutegravir; ABC, Abacavir; 3TC, Lamivudine; FTC, Emtricitabine; TDF, Tenofovir; ETR, Etravirine; EFV, Efavirenz; DRV/r, Danuravir/ritonavir.^‡Drug classes to which resistance was found: PI, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; INSTI, integrase strand transfer inhibitors. No, no mutations. NA, no sequence available.^ƪChange in the treatment due to renal failure.